ArticleCureus2025
Clear Cell Renal Cell Carcinoma With Brain Metastases Treated With Complementary Ketogenic Metabolic Therapy: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 65-year-old woman was first diagnosed in 2011 with stage III clear cell renal cell carcinoma (pT3aNxM0) of the left kidney, managed successfully with radical nephrectomy. She remained disease-free for three years. In 2014, she developed a metachronous stage III papillary thyroid carcinoma (T1N1M0), treated with total thyroidectomy, nodal dissection, and adjuvant radioactive iodine therapy (100 mCi). In 2019, two pulmonary lesions were detected in the left upper lobe. Biopsy confirmed metastatic clear cell carcinoma. Due to intolerance to sunitinib, the patient was treated with pazopanib. By September 2022, she developed four intracranial metastatic lesions, predominantly in the right frontal lobe and bilateral mesial temporal lobes. A neurosurgeon performed a biopsy, confirming metastatic clear cell carcinoma. The patient underwent whole-brain radiotherapy over five sessions and began treatment with nivolumab. After receiving five cycles of immunotherapy, the patient experienced a seizure associated with edema around the dominant lesion and neurological decline. She was treated with anticonvulsants and a short steroid course, leading to functional recovery. We used this treatment for around 10 days and continued immunotherapy and anticonvulsant therapy. In January 2023, ketogenic metabolic therapy (KMT) was initiated using a 3:1 ratio ketogenic supplement (KetoVie). Ketone levels and neurological status were closely monitored. Upon confirmation of ketones in the urine or blood, therapy adjustments were made to optimize adherence. By July 2023, the patient no longer required assistance for medical appointments, discontinued anticonvulsant therapy, and retained full cognitive function. In January 2024, the patient maintained a partial response, and dietary supplementation was stopped. This case highlights the potential role of KMT as a safe and complementary approach in advanced clear cell renal cell carcinoma. KMT may enhance the efficacy of immunotherapy and radiotherapy, contributing to improved progression-free survival and neurological function without increasing toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.